Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049648051> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2049648051 endingPage "328" @default.
- W2049648051 startingPage "328" @default.
- W2049648051 abstract "Objective: To compare oral chlorambucil and intravenous cyclophosphamide-based drug regimens in the treatment of patients with membranous nephropathy and deteriorating renal function. Design: Randomized study. Setting: University hospital and teaching hospitals. Patients: 18 patients with membranous nephropathy, a nephrotic syndrome, and deteriorating renal function. Intervention: Chlorambucil (0.15 mg/kg body weight per day orally in months 2, 4, and 6) and prednisone (three intravenous pulses of 1 g of methylprednisolone followed by oral prednisone at 0.5 mg/kg per day in months 1, 3, and 5) or intravenous cyclophosphamide (750 mg/m2 body surface area once every month for 6 months) and methylprednisolone (three intravenous 1-g pulses in months 1, 3, and 5). Measurements: Serum creatinine, serum cholesterol, serum albumin, and urinary protein levels. Results: Before treatment, no statistical differences were found between the treatment groups. Six months after treatment was started, serum creatinine levels had decreased in the group treated with chlorambucil, methylprednisolone, and prednisone from a mean of 260 ± 112 µmol/L to 186 ± 74 µmol/L (P = 0.003) and had increased in the group treated with intravenous cyclophosphamide and methylprednisolone from 218 ± 85 µmol/L to 297 ± 143 µmol/L (P = 0.02; difference between both groups, P < 0.001). Serum albumin levels increased in both groups by 9 and 6 g/L, respectively, and the urinary protein/creatinine ratio decreased by 2.6 and 3.1 g/10 mmol, respectively. At the end of follow-up (median, 15 months; range, 6 to 36 months), one patient in the chlorambucil group and four patients in the cyclophosphamide group had reached end-stage renal failure after 36, 12, 12, 18, and 18 months of therapy, respectively. One patient in the intravenous cyclophosphamide group died after 6 months of therapy. Conclusions: Thus far, both oral chlorambucil and oral cyclophosphamide have been shown to be effective in the treatment of patients with membranous nephropathy and deteriorating renal function. Our study shows that intermittent monthly pulses of low-dose cyclophosphamide are ineffective in preserving renal function in such patients." @default.
- W2049648051 created "2016-06-24" @default.
- W2049648051 creator A5088636110 @default.
- W2049648051 date "1994-09-01" @default.
- W2049648051 modified "2023-09-25" @default.
- W2049648051 title "Preserving Renal Function in Patients with Membranous Nephropathy: Daily Oral Chlorambucil Compared with Intermittent Monthly Pulses of Cyclophosphamide" @default.
- W2049648051 doi "https://doi.org/10.7326/0003-4819-121-5-199409010-00003" @default.
- W2049648051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8042821" @default.
- W2049648051 hasPublicationYear "1994" @default.
- W2049648051 type Work @default.
- W2049648051 sameAs 2049648051 @default.
- W2049648051 citedByCount "49" @default.
- W2049648051 countsByYear W20496480512012 @default.
- W2049648051 countsByYear W20496480512013 @default.
- W2049648051 countsByYear W20496480512014 @default.
- W2049648051 countsByYear W20496480512017 @default.
- W2049648051 countsByYear W20496480512020 @default.
- W2049648051 countsByYear W20496480512021 @default.
- W2049648051 countsByYear W20496480512022 @default.
- W2049648051 countsByYear W20496480512023 @default.
- W2049648051 crossrefType "journal-article" @default.
- W2049648051 hasAuthorship W2049648051A5088636110 @default.
- W2049648051 hasConcept C126322002 @default.
- W2049648051 hasConcept C126894567 @default.
- W2049648051 hasConcept C134018914 @default.
- W2049648051 hasConcept C141071460 @default.
- W2049648051 hasConcept C159641895 @default.
- W2049648051 hasConcept C2775946357 @default.
- W2049648051 hasConcept C2776694085 @default.
- W2049648051 hasConcept C2776755627 @default.
- W2049648051 hasConcept C2777866208 @default.
- W2049648051 hasConcept C2778720950 @default.
- W2049648051 hasConcept C2778930706 @default.
- W2049648051 hasConcept C2780091579 @default.
- W2049648051 hasConcept C2780306776 @default.
- W2049648051 hasConcept C2780368995 @default.
- W2049648051 hasConcept C2780372218 @default.
- W2049648051 hasConcept C71924100 @default.
- W2049648051 hasConcept C90924648 @default.
- W2049648051 hasConceptScore W2049648051C126322002 @default.
- W2049648051 hasConceptScore W2049648051C126894567 @default.
- W2049648051 hasConceptScore W2049648051C134018914 @default.
- W2049648051 hasConceptScore W2049648051C141071460 @default.
- W2049648051 hasConceptScore W2049648051C159641895 @default.
- W2049648051 hasConceptScore W2049648051C2775946357 @default.
- W2049648051 hasConceptScore W2049648051C2776694085 @default.
- W2049648051 hasConceptScore W2049648051C2776755627 @default.
- W2049648051 hasConceptScore W2049648051C2777866208 @default.
- W2049648051 hasConceptScore W2049648051C2778720950 @default.
- W2049648051 hasConceptScore W2049648051C2778930706 @default.
- W2049648051 hasConceptScore W2049648051C2780091579 @default.
- W2049648051 hasConceptScore W2049648051C2780306776 @default.
- W2049648051 hasConceptScore W2049648051C2780368995 @default.
- W2049648051 hasConceptScore W2049648051C2780372218 @default.
- W2049648051 hasConceptScore W2049648051C71924100 @default.
- W2049648051 hasConceptScore W2049648051C90924648 @default.
- W2049648051 hasIssue "5" @default.
- W2049648051 hasLocation W20496480511 @default.
- W2049648051 hasLocation W20496480512 @default.
- W2049648051 hasOpenAccess W2049648051 @default.
- W2049648051 hasPrimaryLocation W20496480511 @default.
- W2049648051 hasRelatedWork W1981656965 @default.
- W2049648051 hasRelatedWork W2002201599 @default.
- W2049648051 hasRelatedWork W2063849891 @default.
- W2049648051 hasRelatedWork W2073033781 @default.
- W2049648051 hasRelatedWork W2081340978 @default.
- W2049648051 hasRelatedWork W2091817497 @default.
- W2049648051 hasRelatedWork W2337791726 @default.
- W2049648051 hasRelatedWork W2396707624 @default.
- W2049648051 hasRelatedWork W2417582138 @default.
- W2049648051 hasRelatedWork W617728176 @default.
- W2049648051 hasVolume "121" @default.
- W2049648051 isParatext "false" @default.
- W2049648051 isRetracted "false" @default.
- W2049648051 magId "2049648051" @default.
- W2049648051 workType "article" @default.